Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 839

1.

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE.

Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73.

PMID:
8935801
2.
3.

Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.

Leysen JE, Janssen PM, Megens AA, Schotte A.

J Clin Psychiatry. 1994 May;55 Suppl:5-12.

PMID:
7520908
4.
5.
6.

Effects of recent and reference antipsychotic agents at human dopamine D2 and D3 receptor signaling in Chinese hamster ovary cells.

Vanhauwe JF, Ercken M, van de Wiel D, Jurzak M, Leysen JE.

Psychopharmacology (Berl). 2000 Jul;150(4):383-90.

PMID:
10958079
7.

In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone.

Leysen JE, Janssen PM, Gommeren W, Wynants J, Pauwels PJ, Janssen PA.

Mol Pharmacol. 1992 Mar;41(3):494-508.

PMID:
1372084
8.

In vivo receptor occupancy of NRA0045, a putative atypical antipsychotic, in rats.

Chaki S, Funakoshi T, Yoshikawa R, Okuyama S, Kumagai T, Nakazato A, Nagamine M, Tomisawa K.

Neuropharmacology. 1999 Aug;38(8):1185-94.

PMID:
10462131
10.

Novel pharmacological approaches to the treatment of schizophrenia.

Fink-Jensen A.

Dan Med Bull. 2000 Jun;47(3):151-67. Review.

PMID:
10913983
11.

Atypical antipsychotics: mechanism of action.

Seeman P.

Can J Psychiatry. 2002 Feb;47(1):27-38. Review.

PMID:
11873706
12.

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds.

Richelson E, Souder T.

Life Sci. 2000 Nov 24;68(1):29-39.

PMID:
11132243
15.

In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.

AssiƩ MB, Dominguez H, Consul-Denjean N, Newman-Tancredi A.

Naunyn Schmiedebergs Arch Pharmacol. 2006 Sep;373(6):441-50. Epub 2006 Sep 1.

PMID:
16947046
16.

In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol.

Sumiyoshi T, Kido H, Sakamoto H, Urasaki K, Suzuki K, Yamaguchi N, Mori H, Shiba K, Yokogawa K.

Pharmacol Biochem Behav. 1994 Mar;47(3):553-7.

PMID:
7516078
17.

Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors.

Stockmeier CA, DiCarlo JJ, Zhang Y, Thompson P, Meltzer HY.

J Pharmacol Exp Ther. 1993 Sep;266(3):1374-84.

PMID:
8103793
18.

Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.

Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA 3rd, et al.

J Pharmacol Exp Ther. 1995 Oct;275(1):101-13.

PMID:
7562537
19.

Serotonin receptors: their key role in drugs to treat schizophrenia.

Meltzer HY, Li Z, Kaneda Y, Ichikawa J.

Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1159-72. Review.

PMID:
14642974
20.

Dopamine D1, D2 and serotonin2 receptor occupation by typical and atypical antipsychotic drugs in vivo.

Matsubara S, Matsubara R, Kusumi I, Koyama T, Yamashita I.

J Pharmacol Exp Ther. 1993 May;265(2):498-508.

PMID:
7684443

Supplemental Content

Support Center